Impact of the Pentavalent Meningococcal Conjugate Vaccine(NmCV-5) Targeting Serogroups A,C,Y,W, and X on the Sub-Saharan Africa Region

Yuxiang Zhang

doi:10.62051/gmvqsc77

Authors

Yuxiang Zhang

DOI:

https://doi.org/10.62051/gmvqsc77

Keywords:

NmCV-5; Sub-Saharan Africa; Meningococcal disease.

Abstract

Meningococcal disease poses a considerable public health burden in sub-Saharan Africa (SSA), particularly in the "meningitis belt". Although the rollout of the serogroup A meningococcal vaccine (MenAfriVac) has effectively contributed to a significant reduction in the incidence of group A meningitis, serogroups C, W, Y, and X are experiencing rising infection rates, highlighting the urgent need for new vaccines to address the threat posed by non-serogroup A Neisseria meningitidis. Considering this, Serum Institute of India Pvt Ltd., in partnership with PATH, developed a pentavalent conjugate vaccine (NmCV-5) containing capsular polysaccharides of meningococcal serogroups: A, C, W, X and Y, conjugated to a protein carrier, tetanus toxoid. In this paper, the epidemic trend of meningococcal and the development of NmCV-5 vaccine in SSA were analyzed by literature review. It has been shown that the NmCV-5 vaccine demonstrated good safety and immunogenicity against all serogars in clinical trials, especially significant protection against Neisseria meningitidis serogroup X. The single-dose schedule of the vaccine also improves roll-out feasibility in resource-limited Settings. However, the rollout of the vaccine still faces challenges such as poor infrastructure and insufficient public awareness.

Downloads

Download data is not yet available.

References

[1] Nakamura, T., Cohen, A. L., Schwartz, S., Mwenda, J. M., Weldegebriel, G., Biey, J. N. M., Katsande, R., Ghoniem, A., Fahmy, K., Rahman, H. A., Videbaek, D., Daniels, D., Singh, S., Wasley, A., Rey-Benito, G., de Oliveira, L., Ortiz, C., Tondo, E., Liyanage, J. B. L., Sharifuzzaman, M., … Serhan, F. (2021). The Global Landscape of Pediatric Bacterial Meningitis Data Reported to the World Health Organization-Coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014-2019. The Journal of infectious diseases, 224(12 Suppl 2), S161–S173.

[2] Patel, J. C., Soeters, H. M., Diallo, A. O., Bicaba, B. W., Kadadé, G., Dembélé, A. Y., ... & MenAfriNet Consortium. (2019). MenAfriNet: a network supporting case-based meningitis surveillance and vaccine evaluation in the meningitis belt of Africa. The Journal of infectious diseases, 220(Supplement_4), S148-S154.

[3] Fernandez, K., Lingani, C., Aderinola, O. M., Goumbi, K., Bicaba, B., Edea, Z. A., ... & Ronveaux, O. (2019). Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011–2017. The Journal of infectious diseases, 220(Supplement_4), S225-S232.

[4] Purmohamad, A., Abasi, E., Azimi, T., Hosseini, S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019). Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microbial pathogenesis, 134, 103571.

[5] Viviani, S. (2022). Efficacy and effectiveness of the meningococcal conjugate Group A vaccine MenAfriVac® in preventing recurrent meningitis epidemics in Sub-Saharan Africa. Vaccines, 10(4), 617.

[6] Mustapha, M. M., & Harrison, L. H. (2018). Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. Human Vaccines & Immunotherapeutics, 14(5), 1107-1115.

[7] Goldblatt, D. (2000). Conjugate vaccines. Clinical & Experimental Immunology, 119(1), 1-3.

[8] Marshall, G. S., Fergie, J., Presa, J., & Peyrani, P. (2022). Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infectious Diseases and Therapy, 11(3), 937-951.

[9] Purmohamad, A., Abasi, E., Azimi, T., Hosseini, S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019). Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microbial pathogenesis, 134, 103571.

[10] Chen, W. H., Neuzil, K. M., Boyce, C. R., Pasetti, M. F., Reymann, M. K., Martellet, L., ... & Alderson, M. R. (2018). Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. The Lancet Infectious Diseases, 18(10), 1088-1096.

[11] Tapia, M. D., Sow, S. O., Naficy, A., Diallo, F., Haidara, F. C., Chaudhari, A., ... & Kulkarni, P. S. (2021). Meningococcal serogroup ACWYX conjugate vaccine in Malian toddlers. New England Journal of Medicine, 384(22), 2115-2123.

[12] Haidara, F. C., Umesi, A., Sow, S. O., Ochoge, M., Diallo, F., Imam, A., Traore, Y., Affleck, L., Doumbia, M. F., Daffeh, B., Kodio, M., Wariri, O., Traoré, A., Jallow, E., Kampmann, B., Kapse, D., Kulkarni, P. S., Mallya, A., Goel, S., Sharma, P., … Clarke, E. (2023). Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. The New England journal of medicine, 388(21), 1942–1955.

[13] Steffen, R., & Caumes, E. (2024). Three novel pentavalent meningococcal vaccines. Journal of Travel Medicine, 31(1), taad152.

[14] See also WHO Meningitis Weekly Bulletin, https://www.who.int/publications/m/item/meningitis-weekly-bulletin-1-to-7-may-2023

[15] Haidara, F. C., Umesi, A., Sow, S. O., Ochoge, M., Diallo, F., Imam, A., ... & Clarke, E. (2023). Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. New England Journal of Medicine, 388(21), 1942-1955.

[16] Bangura, J. B., Xiao, S., Qiu, D., Ouyang, F., & Chen, L. (2020). Barriers to childhood immunization in sub-Saharan Africa: a systematic review. BMC public health, 20, 1-15.